Riccardo Soffietti1, Chetan Bettegowda2, Ingo K Mellinghoff3, Katherine E Warren4, Manmeet S Ahluwalia5, John F De Groot6, Evanthia Galanis7, Mark R Gilbert8, Kurt A Jaeckle9, Emilie Le Rhun10, Roberta Rudà11, Joan Seoane12, Niklas Thon13, Yoshie Umemura14, Michael Weller15, Martin J van den Bent16, Michael A Vogelbaum17, Susan M Chang18, Patrick Y Wen19. 1. Division of Neuro-Oncology, Department of Neuroscience, University and City of Health and Science Hospital, Turin, Italy. 2. Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 3. Department of Neurology, Memorial Sloan Kettering Cancer Center New York, USA. 4. Department of Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. 5. Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, Ohio, USA. 6. Department of Neuro-Oncology, University of Texas, MD Anderson Cancer Center Houston, Houston, Texas, USA. 7. Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA. 8. Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. 9. Department of Neurology, Mayo Clinic Florida, Jacksonville, Florida, USA. 10. Departments of Neurology & Neurosurgery, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland. 11. Department of Neurology, Castelfranco Veneto/Treviso Hospital and Division of Neuro-Oncology, Department of Neuroscience, University of Turin, Turin, Italy. 12. Vall d'Hebron Institute of Oncology (VHIO) University Hospital, Universitat Autònoma de Barcelona, ICREA,CIBERONC, Barcelona, Spain. 13. Division of Neuro-Oncology, Department of Neurosurgery, Ludwig Maximilians University School of Medicine, Munich, Germany. 14. Division of Neuro-Oncology, Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA. 15. Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland. 16. Department of Neurology, Brain Tumor Center at Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands. 17. Department of Neurosurgery, Cleveland Clinic, Cleveland, Ohio, USA. 18. Division of Neuro-Oncology, University of California San Francisco, San Francisco, California, USA. 19. Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.
Abstract
BACKGROUND: There is an extensive literature highlighting the utility of blood-based liquid biopsies in several extracranial tumors for diagnosis and monitoring. METHODS: The RANO (Response Assessment in Neuro-Oncology) group developed a multidisciplinary international Task Force to review the English literature on liquid biopsy in gliomas focusing on the most frequently used techniques, that is circulating tumor DNA, circulating tumor cells, and extracellular vesicles in blood and CSF. RESULTS: ctDNA has a higher sensitivity and capacity to represent the spatial and temporal heterogeneity in comparison to circulating tumor cells. Exosomes have the advantages to cross an intact blood-brain barrier and carry also RNA, miRNA, and proteins. Several clinical applications of liquid biopsies are suggested: to establish a diagnosis when tissue is not available, monitor the residual disease after surgery, distinguish progression from pseudoprogression, and predict the outcome. CONCLUSIONS: There is a need for standardization of biofluid collection, choice of an analyte, and detection strategies along with rigorous testing in future clinical trials to validate findings and enable entry into clinical practice.
BACKGROUND: There is an extensive literature highlighting the utility of blood-based liquid biopsies in several extracranial tumors for diagnosis and monitoring. METHODS: The RANO (Response Assessment in Neuro-Oncology) group developed a multidisciplinary international Task Force to review the English literature on liquid biopsy in gliomas focusing on the most frequently used techniques, that is circulating tumor DNA, circulating tumor cells, and extracellular vesicles in blood and CSF. RESULTS: ctDNA has a higher sensitivity and capacity to represent the spatial and temporal heterogeneity in comparison to circulating tumor cells. Exosomes have the advantages to cross an intact blood-brain barrier and carry also RNA, miRNA, and proteins. Several clinical applications of liquid biopsies are suggested: to establish a diagnosis when tissue is not available, monitor the residual disease after surgery, distinguish progression from pseudoprogression, and predict the outcome. CONCLUSIONS: There is a need for standardization of biofluid collection, choice of an analyte, and detection strategies along with rigorous testing in future clinical trials to validate findings and enable entry into clinical practice.
Authors: Rocco Lucero; Valentina Zappulli; Alessandro Sammarco; Oscar D Murillo; Pike See Cheah; Srimeenakshi Srinivasan; Eric Tai; David T Ting; Zhiyun Wei; Matthew E Roth; Louise C Laurent; Anna M Krichevsky; Xandra O Breakefield; Aleksandar Milosavljevic Journal: Cell Rep Date: 2020-02-18 Impact factor: 9.423
Authors: Sabine Mueller; Payal Jain; Winnie S Liang; Lindsay Kilburn; Cassie Kline; Nalin Gupta; Eshini Panditharatna; Suresh N Magge; Bo Zhang; Yuankun Zhu; John R Crawford; Anu Banerjee; Kellie Nazemi; Roger J Packer; Claudia K Petritsch; Nathalene Truffaux; Alison Roos; Sara Nasser; Joanna J Phillips; David Solomon; Annette Molinaro; Angela J Waanders; Sara A Byron; Michael E Berens; John Kuhn; Javad Nazarian; Michael Prados; Adam C Resnick Journal: Int J Cancer Date: 2019-04-03 Impact factor: 7.396
Authors: Aadel A Chaudhuri; Jacob J Chabon; Alexander F Lovejoy; Aaron M Newman; Henning Stehr; Tej D Azad; Michael S Khodadoust; Mohammad Shahrokh Esfahani; Chih Long Liu; Li Zhou; Florian Scherer; David M Kurtz; Carmen Say; Justin N Carter; David J Merriott; Jonathan C Dudley; Michael S Binkley; Leslie Modlin; Sukhmani K Padda; Michael F Gensheimer; Robert B West; Joseph B Shrager; Joel W Neal; Heather A Wakelee; Billy W Loo; Ash A Alizadeh; Maximilian Diehn Journal: Cancer Discov Date: 2017-09-24 Impact factor: 39.397
Authors: Florent Mouliere; Richard Mair; Dineika Chandrananda; Francesco Marass; Christopher G Smith; Jing Su; James Morris; Colin Watts; Kevin M Brindle; Nitzan Rosenfeld Journal: EMBO Mol Med Date: 2018-12 Impact factor: 12.137
Authors: Johan Skog; Tom Würdinger; Sjoerd van Rijn; Dimphna H Meijer; Laura Gainche; Miguel Sena-Esteves; William T Curry; Bob S Carter; Anna M Krichevsky; Xandra O Breakefield Journal: Nat Cell Biol Date: 2008-11-16 Impact factor: 28.824
Authors: Leticia De Mattos-Arruda; Regina Mayor; Charlotte K Y Ng; Britta Weigelt; Francisco Martínez-Ricarte; Davis Torrejon; Mafalda Oliveira; Alexandra Arias; Carolina Raventos; Jiabin Tang; Elena Guerini-Rocco; Elena Martínez-Sáez; Sergio Lois; Oscar Marín; Xavier de la Cruz; Salvatore Piscuoglio; Russel Towers; Ana Vivancos; Vicente Peg; Santiago Ramon y Cajal; Joan Carles; Jordi Rodon; María González-Cao; Josep Tabernero; Enriqueta Felip; Joan Sahuquillo; Michael F Berger; Javier Cortes; Jorge S Reis-Filho; Joan Seoane Journal: Nat Commun Date: 2015-11-10 Impact factor: 14.919
Authors: Adrienne Boire; Dieta Brandsma; Priscilla K Brastianos; Emilie Le Rhun; Manmeet Ahluwalia; Larry Junck; Michael Glantz; Morris D Groves; Eudocia Q Lee; Nancy Lin; Jeffrey Raizer; Roberta Rudà; Michael Weller; Martin J Van den Bent; Michael A Vogelbaum; Susan Chang; Patrick Y Wen; Riccardo Soffietti Journal: Neuro Oncol Date: 2019-05-06 Impact factor: 12.300